Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs
May 18, 2022 07:30 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Participation in 2022 RBC Capital Markets Global Healthcare Conference
May 17, 2022 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Names Bruce Rogers as President of Morphic Therapeutic and Blaise Lippa as Chief Scientific Officer
May 12, 2022 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2022
May 04, 2022 08:00 ET
|
Morphic Therapeutic
Initiated EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Described new understanding of α4β7-expressing immune cells and MORF-057 dose response in oral presentation at ECCO...
Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development
April 06, 2022 08:00 ET
|
Morphic Therapeutic
Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron Pelta promoted to Senior Vice President, Business and Corporate Development;...
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
March 30, 2022 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Initiation of EMERALD-1 Phase 2a Clinical Trial of MORF-057 in Patients with Ulcerative Colitis
March 25, 2022 08:00 ET
|
Morphic Therapeutic
MORF-057, an oral α4β7 integrin inhibitor candidate, holds potential for treating inflammatory bowel diseases Phase 2b EMERALD-2 clinical trial of MORF-057 expected to begin mid-year 2022 WALTHAM,...
Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference
March 04, 2022 09:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., March 04, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021
February 24, 2022 07:30 ET
|
Morphic Therapeutic
Presented positive Phase 1 data for MORF-057 Phase 2a trial in patients with ulcerative colitis scheduled to begin 1Q22; Phase 2b to commence mid-year Presented preclinical data from αvβ8 program at...
Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022
February 22, 2022 08:00 ET
|
Morphic Therapeutic
New preclinical data expand understanding of α4β7-expressing immune cells and MORF-057 dose response Data support ongoing clinical development program in IBD WALTHAM, Mass., Feb. 22, 2022 ...